Media stories about Ascendis Pharma (NASDAQ:ASND) have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ascendis Pharma earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.7008632930493 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Ascendis Pharma opened at $66.50 on Friday, according to MarketBeat. Ascendis Pharma has a fifty-two week low of $21.95 and a fifty-two week high of $70.50. The stock has a market cap of $2.77 billion, a PE ratio of -15.36 and a beta of 0.65.
Ascendis Pharma (NASDAQ:ASND) last issued its earnings results on Wednesday, March 28th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.16). Ascendis Pharma had a negative return on equity of 74.67% and a negative net margin of 8,156.09%. The business had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.58 million. research analysts forecast that Ascendis Pharma will post -3.8 earnings per share for the current fiscal year.
ASND has been the topic of a number of analyst reports. ValuEngine raised Ascendis Pharma from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Bank of America raised their target price on Ascendis Pharma from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, January 25th. Credit Suisse Group reissued a “buy” rating and set a $50.00 target price on shares of Ascendis Pharma in a research report on Sunday, February 25th. Zacks Investment Research raised Ascendis Pharma from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, Leerink Swann reissued a “market perform” rating and set a $64.00 target price (up previously from $37.00) on shares of Ascendis Pharma in a research report on Monday, April 2nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $67.33.
Ascendis Pharma Company Profile
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Receive News & Ratings for Ascendis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.